BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28273184)

  • 1. [How can we treat Waldenström's macroglobulinemia?].
    Mucsi AO; Nagy Z
    Magy Onkol; 2017 Mar; 61(1):12-20. PubMed ID: 28273184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.
    Chin CK; Leslie C; Grove CS; Van Vliet C; Cheah CY
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
    Grunenberg A; Buske C
    Internist (Berl); 2016 Mar; 57(3):238-44. PubMed ID: 26830425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to manage Waldenstrom's macroglobulinemia.
    Buske C; Leblond V
    Leukemia; 2013 Apr; 27(4):762-72. PubMed ID: 23385376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.
    Kyle RA; Ansell SM; Kapoor P
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):179-186. PubMed ID: 27825464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Waldenstrom's macroglobulinemia].
    Geller LI
    Probl Gematol Pereliv Krovi; 1969 Feb; 14(2):40-9. PubMed ID: 4981803
    [No Abstract]   [Full Text] [Related]  

  • 8. [Waldenström's macroglobulinemia: clinical aspects, diagnosis and therapy].
    Baldus M; Brass H
    Med Klin (Munich); 1992 Aug; 87(8):434-6. PubMed ID: 1406477
    [No Abstract]   [Full Text] [Related]  

  • 9. Updates in prognostication and treatment of Waldenström's macroglobulinemia.
    Advani P; Paulus A; Ailawadhi S
    Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):179-188. PubMed ID: 31158330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.
    Ni H; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Hitoshi Y; Ansell SM; Treon SP; Thomas SK; Lee HC; Wang Z; Davis RE; Orlowski RZ
    Clin Cancer Res; 2018 Dec; 24(24):6408-6420. PubMed ID: 30126942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
    Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Waldenström's macroglobulinemia with an uncommon presentation].
    Trueba F; Maslin J; Coutant G; Guymar S; Vigezzi JF; Desangles F; Nizou JY; Nicand E
    Ann Biol Clin (Paris); 2006; 64(1):73-5. PubMed ID: 16420993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
    Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Ilizaliturri F; Huff CA; Kassim A; Krishnan AY; Medeiros BC; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Tricot G; Weber DM; Yahalom J; Yunus F; Kumar R; Shead DA;
    J Natl Compr Canc Netw; 2012 Oct; 10(10):1211-9. PubMed ID: 23054875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis.
    Merlini G; Sarosiek S; Benevolo G; Cao X; Dimopoulos M; Garcia-Sanz R; Gatt ME; Fernandez de Larrea C; San-Miguel J; Treon SP; Minnema MC
    Semin Hematol; 2023 Mar; 60(2):113-117. PubMed ID: 37099030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
    Buske C; Sadullah S; Kastritis E; Tedeschi A; García-Sanz R; Bolkun L; Leleu X; Willenbacher W; Hájek R; Minnema MC; Cheng M; Bilotti E; Graef T; Dimopoulos MA;
    Lancet Haematol; 2018 Jul; 5(7):e299-e309. PubMed ID: 29958569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal clues apparently distinguishing Waldenstrom's macroglobulinemia from multiple myeloma and leukemia.
    Rothschild BM; Ruhli F; Rothschild C
    Am J Hum Biol; 2002; 14(4):532-7. PubMed ID: 12112574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to manage waldenström's macroglobulinemia in 2024.
    Grunenberg A; Buske C
    Cancer Treat Rev; 2024 Apr; 125():102715. PubMed ID: 38471356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.
    Hunter ZR; Manning RJ; Hanzis C; Ciccarelli BT; Ioakimidis L; Patterson CJ; Lewicki MC; Tseng H; Gong P; Liu X; Zhou Y; Yang G; Sun J; Xu L; Sheehy P; Morra M; Treon SP
    Haematologica; 2010 Mar; 95(3):470-5. PubMed ID: 19903677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous Waldenström's macroglobulinemia: report of a case and overview of the spectrum of cutaneous disease.
    Libow LF; Mawhinney JP; Bessinger GT
    J Am Acad Dermatol; 2001 Dec; 45(6 Suppl):S202-6. PubMed ID: 11712059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.